ArticleScientific reports2026
Nano-liposomal delivery of Gracilaria corticata bioactive peptides for improved stability and controlled gastrointestinal release.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to develop and evaluate a liposomal nano-delivery system for bioactive peptide fractions (PFs) derived from Gracilaria corticata algae proteins. The peptides were obtained by enzymatic hydrolysis using alcalase, pancreatin, and trypsin. The resulting PF-loaded nanoliposomes were characterized in terms of degree of hydrolysis (DH), particle size, ζ-potential, encapsulation efficiency (EE), and antioxidant capacity (DPPH and ABTS assays). Among the tested enzymes, alcalase produced hydrolysates with the highest DH (33%) and EE (84%). The particle size of nanoliposomes ranged from 68.1 to 78.1 nm, with PDI values between 0.28 and 0.32, indicating good size uniformity. ζ-potential values became more negative upon PF encapsulation (from - 7.90 to - 15.80 mV), enhancing colloidal stability. Antioxidant activity of the PF-loaded liposomes was preserved, with maximum DPPH and ABTS radical scavenging observed for alcalase and pancreatin hydrolysates, respectively. Hydrolysates obtained with alcalase were chosen for further studies. Further structural and thermal analyses (TEM, FTIR, and DSC) confirmed successful PF encapsulation and improved thermal stability. TEM and FTIR analyses confirmed the spherical morphology and successful peptide encapsulation within the liposomal bilayer. In vitro release studies in simulated gastric and intestinal fluids demonstrated sustained release, with minimal PF release (7.45%) in gastric conditions and controlled release up to 95.4% under intestinal conditions. These findings suggest that nano-liposomal encapsulation is an effective strategy to enhance the stability, bioactivity, and delivery of marine-derived peptides in functional food or nutraceutical applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.